Annals of Hematology

, Volume 91, Issue 2, pp 291–294 | Cite as

Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma

  • Shih-Hung Yang
  • Long-Wei Lin
  • Yu-Jen Fang
  • Ann-Lii Cheng
  • Sung-Hsin Kuo
Letter to the Editor

References

  1. 1.
    Daum S, Ullrich R, Heise W et al (2003) Intestinal non-Hodgkin’s lymphoma: a multicenter prospective clinical study from the German study group on intestinal non-Hodgkin’s lymphoma. J Clin Oncol 21:2740–2746PubMedCrossRefGoogle Scholar
  2. 2.
    Friedberg JW, Fisher RI (2008) Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am 22:941–952PubMedCrossRefGoogle Scholar
  3. 3.
    Aksoy S, Harputluoglu H, Kilickap S et al (2007) Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48:1307–1312PubMedCrossRefGoogle Scholar
  4. 4.
    Kuo SH, Lin LI, Chang CJ et al (2002) Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy. J Clin Microbiol 40:3909–3912PubMedCrossRefGoogle Scholar
  5. 5.
    Langnas AN, Markin RS, Cattral MS et al (1995) Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology 22:1661–1665PubMedGoogle Scholar
  6. 6.
    Karetnyi YV, Beck PR, Markin RS et al (1999) Human parvovirus B19 infection in acute fulminant liver failure. Arch Virol 144:1713–1724PubMedCrossRefGoogle Scholar
  7. 7.
    Quemelo PR, Lima DM, da Fonseca BA et al (2007) Detection of parvovirus B19 infection in formalin-fixed and paraffin-embedded placenta and fetal tissues. Rev Inst Med Trop São Paulo 49:103–107PubMedCrossRefGoogle Scholar
  8. 8.
    Hsu TC, Tsay GJ (2001) Human parvovirus B19 infection in patients with systemic lupus erythematosus. Rheumatol (Oxf) 40:152–157CrossRefGoogle Scholar
  9. 9.
    Wang C, Heim A, Schlaphoff V et al (2009) Intrahepatic long-term persistence of parvovirus B19 and its role in chronic viral hepatitis. J Med Virol 81:2079–2088PubMedCrossRefGoogle Scholar
  10. 10.
    Hartmann JT, Meisinger I, Kröber SM et al (2006) Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma. Haematologica 91(12 Suppl):ECR49PubMedGoogle Scholar
  11. 11.
    Hillingsø JG, Jensen IP, Tom-Petersen L (1998) Parvovirus B19 and acute hepatitis in adults. Lancet 351:955–956PubMedGoogle Scholar
  12. 12.
    Yang SH, Kuo SH (2008) Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 87:325–327PubMedCrossRefGoogle Scholar
  13. 13.
    McLaughlin P, Grillo-Lo’pez A, Link BK et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Shih-Hung Yang
    • 1
    • 4
  • Long-Wei Lin
    • 2
  • Yu-Jen Fang
    • 3
  • Ann-Lii Cheng
    • 4
    • 5
    • 6
  • Sung-Hsin Kuo
    • 1
    • 4
    • 5
    • 6
  1. 1.Department of OncologyNational Taiwan University Hospital, Yun-Lin BranchYunlinTaiwan
  2. 2.Department of PathologyNational Taiwan University Hospital, Yun-Lin BranchYunlinTaiwan
  3. 3.Department of Internal MedicineNational Taiwan University Hospital, Yun-Lin BranchYunlinTaiwan
  4. 4.Department of OncologyNational Taiwan University Hospital and National Taiwan University College of MedicineTaipeiTaiwan
  5. 5.Department of Internal MedicineNational Taiwan University Hospital and National Taiwan University College of MedicineTaipeiTaiwan
  6. 6.Cancer Research CenterNational Taiwan University College of MedicineTaipeiTaiwan

Personalised recommendations